These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2036861)

  • 1. Interaction between carbamazepine and antituberculosis agents.
    Fleenor ME; Harden JW; Curtis G
    Chest; 1991 Jun; 99(6):1554. PubMed ID: 2036861
    [No Abstract]   [Full Text] [Related]  

  • 2. Gynaecomastia during antituberculosis chemotherapy with isoniazid.
    Dixit R; Sharma S; Nawal CL
    J Assoc Physicians India; 2008 May; 56():390-1. PubMed ID: 18700651
    [No Abstract]   [Full Text] [Related]  

  • 3. Antituberculous therapy and acute liver function.
    Bourke SJ; White J; Stenton SC; Hendrick DJ
    Lancet; 1995 May; 345(8958):1171-2. PubMed ID: 7786347
    [No Abstract]   [Full Text] [Related]  

  • 4. Pyrazinamide-induced sideroblastic anemia.
    Colucci G; Silzle T; Solenthaler M
    Am J Hematol; 2012 Mar; 87(3):305. PubMed ID: 21818765
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapy of tuberculosis in the adult].
    Schrappe M; Wassermann K; Kroegel C
    Med Klin (Munich); 1995 Apr; 90(4):229-30. PubMed ID: 7776936
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple Drug Hypersensitivity Syndrome to Antituberculosis Drugs: A Case Report.
    Carneiro-Leão L; Gomes I; Freitas C; Costa E Silva M; Viseu R; Cernadas J
    J Investig Allergol Clin Immunol; 2020; 30(1):70-71. PubMed ID: 31530510
    [No Abstract]   [Full Text] [Related]  

  • 7. [The interest of addiction to first line anti-TB drugs].
    Aniked S; Bakouh O; Bourkadi JE
    Pan Afr Med J; 2014; 19():207. PubMed ID: 25821550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
    Sharma SK; Singla R; Sarda P; Mohan A; Makharia G; Jayaswal A; Sreenivas V; Singh S
    Clin Infect Dis; 2010 Mar; 50(6):833-9. PubMed ID: 20156055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of tuberculous meningitis complicated with multiple drug hypersensitivity to antituberculosis agents].
    Arai M
    Rinsho Shinkeigaku; 2015; 55(2):123-5. PubMed ID: 25746078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate.
    Chang KC; Leung CC
    Clin Infect Dis; 2010 Aug; 51(3):366-7; author reply 367-8. PubMed ID: 20597681
    [No Abstract]   [Full Text] [Related]  

  • 11. [Side effects of various combinations of rifampin and isoniazid with ethambutol or streptomycin and pyrazinamide in short-term chemotherapy of newly-detected pulmonary tuberculosis].
    Zierski M; Bek E
    Pneumonol Pol; 1980 Jul; 48(7):469-79. PubMed ID: 7433146
    [No Abstract]   [Full Text] [Related]  

  • 12. Antituberculous therapy and acute liver function.
    Ong EL
    Lancet; 1995 May; 345(8958):1171. PubMed ID: 7723557
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cutaneous reaction after pyrazinamide initiation].
    Mulliez P; Mbassi Fouda FL; Roy Saint-Georges F
    Med Mal Infect; 2011 Sep; 41(9):499-500. PubMed ID: 21458177
    [No Abstract]   [Full Text] [Related]  

  • 14. [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].
    Camacho A; Pérez-Camacho I; Rivero A; Natera C; García-Lázaro M; Castón JJ; Gallo M; Kindelán JM; Torre-Cisneros J
    Enferm Infecc Microbiol Clin; 2010 Apr; 28(4):239-44. PubMed ID: 19647900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oral desensitization to antitubercular agents].
    Drira I; Souissi R; Dakhlaoui R; Jeguirim MS; Chebbi ML
    Rev Pneumol Clin; 1997; 53(2):104-6. PubMed ID: 9205691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antituberculosis drugs and hepatotoxicity.
    Sharma SK
    Infect Genet Evol; 2004 Jun; 4(2):167-70. PubMed ID: 15157635
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
    Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R
    Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatoxic reaction to antituberculous drugs: Adjustments to therapeutic regimen.
    O'Brien RJ
    JAMA; 1991 Jun; 265(24):3323. PubMed ID: 2046117
    [No Abstract]   [Full Text] [Related]  

  • 19. Tuberculosis control programme guidelines--treatment regimens.
    Durrheim DN; Belt EL
    S Afr Med J; 1996 Oct; 86(10):1293-4. PubMed ID: 8955740
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
    Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.